The global market for Multiple Sclerosis (MS) Drugs was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Multiple Sclerosis (MS) Drugs, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Multiple Sclerosis (MS) Drugs by region & country, by Type, and by Application.
The Multiple Sclerosis (MS) Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Multiple Sclerosis (MS) Drugs.
Market Segmentation
By Company
Bayer AG
Bayhill Therapeutics
Biogen Idec
Cinnagen
Daiichi Sankyo
Eli Lilly
Fast Forward Llc
Antisense Therapeutics
Apitope
Five Prime Therapeutics
Genmab
Artielle Immunotherapeutics
Genzyme
Glaxosmithkline
Gw Pharmaceuticals
Innate Immunotherapeutics
Segment by Type:
Copaxone (Glatiramer Acetate, Copolymer 1)
Novantrone (Mitoxantrone)
Gilenya (Fingolimod, Fty720)
Aubagio (Teriflunomide)
Tecfidera (Dimethyl Fumarate)
Firategrast (Sb683699, T-0047)
Siponimod (Baf312)
Others
Segment by Application
RRMS
SPMS
PPMS
PRMS
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Multiple Sclerosis (MS) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Multiple Sclerosis (MS) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Multiple Sclerosis (MS) Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Market Overview
1.1 Multiple Sclerosis (MS) Drugs Product Introduction
1.2 Global Multiple Sclerosis (MS) Drugs Market Size Forecast
1.2.1 Global Multiple Sclerosis (MS) Drugs Sales Value (2019-2030)
1.2.2 Global Multiple Sclerosis (MS) Drugs Sales Volume (2019-2030)
1.2.3 Global Multiple Sclerosis (MS) Drugs Sales Price (2019-2030)
1.3 Multiple Sclerosis (MS) Drugs Market Trends & Drivers
1.3.1 Multiple Sclerosis (MS) Drugs Industry Trends
1.3.2 Multiple Sclerosis (MS) Drugs Market Drivers & Opportunity
1.3.3 Multiple Sclerosis (MS) Drugs Market Challenges
1.3.4 Multiple Sclerosis (MS) Drugs Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Multiple Sclerosis (MS) Drugs Players Revenue Ranking (2023)
2.2 Global Multiple Sclerosis (MS) Drugs Revenue by Company (2019-2024)
2.3 Global Multiple Sclerosis (MS) Drugs Players Sales Volume Ranking (2023)
2.4 Global Multiple Sclerosis (MS) Drugs Sales Volume by Company Players (2019-2024)
2.5 Global Multiple Sclerosis (MS) Drugs Average Price by Company (2019-2024)
2.6 Key Manufacturers Multiple Sclerosis (MS) Drugs Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Multiple Sclerosis (MS) Drugs Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Multiple Sclerosis (MS) Drugs
2.9 Multiple Sclerosis (MS) Drugs Market Competitive Analysis
2.9.1 Multiple Sclerosis (MS) Drugs Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Multiple Sclerosis (MS) Drugs Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Multiple Sclerosis (MS) Drugs as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Copaxone (Glatiramer Acetate, Copolymer 1)
3.1.2 Novantrone (Mitoxantrone)
3.1.3 Gilenya (Fingolimod, Fty720)
3.1.4 Aubagio (Teriflunomide)
3.1.5 Tecfidera (Dimethyl Fumarate)
3.1.6 Firategrast (Sb683699, T-0047)
3.1.7 Siponimod (Baf312)
3.1.8 Others
3.2 Global Multiple Sclerosis (MS) Drugs Sales Value by Type
3.2.1 Global Multiple Sclerosis (MS) Drugs Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Multiple Sclerosis (MS) Drugs Sales Value, by Type (2019-2030)
3.2.3 Global Multiple Sclerosis (MS) Drugs Sales Value, by Type (%) (2019-2030)
3.3 Global Multiple Sclerosis (MS) Drugs Sales Volume by Type
3.3.1 Global Multiple Sclerosis (MS) Drugs Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Multiple Sclerosis (MS) Drugs Sales Volume, by Type (2019-2030)
3.3.3 Global Multiple Sclerosis (MS) Drugs Sales Volume, by Type (%) (2019-2030)
3.4 Global Multiple Sclerosis (MS) Drugs Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 RRMS
4.1.2 SPMS
4.1.3 PPMS
4.1.4 PRMS
4.2 Global Multiple Sclerosis (MS) Drugs Sales Value by Application
4.2.1 Global Multiple Sclerosis (MS) Drugs Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Multiple Sclerosis (MS) Drugs Sales Value, by Application (2019-2030)
4.2.3 Global Multiple Sclerosis (MS) Drugs Sales Value, by Application (%) (2019-2030)
4.3 Global Multiple Sclerosis (MS) Drugs Sales Volume by Application
4.3.1 Global Multiple Sclerosis (MS) Drugs Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Multiple Sclerosis (MS) Drugs Sales Volume, by Application (2019-2030)
4.3.3 Global Multiple Sclerosis (MS) Drugs Sales Volume, by Application (%) (2019-2030)
4.4 Global Multiple Sclerosis (MS) Drugs Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Multiple Sclerosis (MS) Drugs Sales Value by Region
5.1.1 Global Multiple Sclerosis (MS) Drugs Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Multiple Sclerosis (MS) Drugs Sales Value by Region (2019-2024)
5.1.3 Global Multiple Sclerosis (MS) Drugs Sales Value by Region (2025-2030)
5.1.4 Global Multiple Sclerosis (MS) Drugs Sales Value by Region (%), (2019-2030)
5.2 Global Multiple Sclerosis (MS) Drugs Sales Volume by Region
5.2.1 Global Multiple Sclerosis (MS) Drugs Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Multiple Sclerosis (MS) Drugs Sales Volume by Region (2019-2024)
5.2.3 Global Multiple Sclerosis (MS) Drugs Sales Volume by Region (2025-2030)
5.2.4 Global Multiple Sclerosis (MS) Drugs Sales Volume by Region (%), (2019-2030)
5.3 Global Multiple Sclerosis (MS) Drugs Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Multiple Sclerosis (MS) Drugs Sales Value, 2019-2030
5.4.2 North America Multiple Sclerosis (MS) Drugs Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Multiple Sclerosis (MS) Drugs Sales Value, 2019-2030
5.5.2 Europe Multiple Sclerosis (MS) Drugs Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Multiple Sclerosis (MS) Drugs Sales Value, 2019-2030
5.6.2 Asia Pacific Multiple Sclerosis (MS) Drugs Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Multiple Sclerosis (MS) Drugs Sales Value, 2019-2030
5.7.2 South America Multiple Sclerosis (MS) Drugs Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Multiple Sclerosis (MS) Drugs Sales Value, 2019-2030
5.8.2 Middle East & Africa Multiple Sclerosis (MS) Drugs Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Multiple Sclerosis (MS) Drugs Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Multiple Sclerosis (MS) Drugs Sales Value
6.2.1 Key Countries/Regions Multiple Sclerosis (MS) Drugs Sales Value, 2019-2030
6.2.2 Key Countries/Regions Multiple Sclerosis (MS) Drugs Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Multiple Sclerosis (MS) Drugs Sales Value, 2019-2030
6.3.2 United States Multiple Sclerosis (MS) Drugs Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Multiple Sclerosis (MS) Drugs Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Multiple Sclerosis (MS) Drugs Sales Value, 2019-2030
6.4.2 Europe Multiple Sclerosis (MS) Drugs Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Multiple Sclerosis (MS) Drugs Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Multiple Sclerosis (MS) Drugs Sales Value, 2019-2030
6.5.2 China Multiple Sclerosis (MS) Drugs Sales Value by Type (%), 2023 VS 2030
6.5.3 China Multiple Sclerosis (MS) Drugs Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Multiple Sclerosis (MS) Drugs Sales Value, 2019-2030
6.6.2 Japan Multiple Sclerosis (MS) Drugs Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Multiple Sclerosis (MS) Drugs Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Multiple Sclerosis (MS) Drugs Sales Value, 2019-2030
6.7.2 South Korea Multiple Sclerosis (MS) Drugs Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Multiple Sclerosis (MS) Drugs Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Multiple Sclerosis (MS) Drugs Sales Value, 2019-2030
6.8.2 Southeast Asia Multiple Sclerosis (MS) Drugs Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Multiple Sclerosis (MS) Drugs Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Multiple Sclerosis (MS) Drugs Sales Value, 2019-2030
6.9.2 India Multiple Sclerosis (MS) Drugs Sales Value by Type (%), 2023 VS 2030
6.9.3 India Multiple Sclerosis (MS) Drugs Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Bayer AG
7.1.1 Bayer AG Company Information
7.1.2 Bayer AG Introduction and Business Overview
7.1.3 Bayer AG Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Bayer AG Multiple Sclerosis (MS) Drugs Product Offerings
7.1.5 Bayer AG Recent Development
7.2 Bayhill Therapeutics
7.2.1 Bayhill Therapeutics Company Information
7.2.2 Bayhill Therapeutics Introduction and Business Overview
7.2.3 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Product Offerings
7.2.5 Bayhill Therapeutics Recent Development
7.3 Biogen Idec
7.3.1 Biogen Idec Company Information
7.3.2 Biogen Idec Introduction and Business Overview
7.3.3 Biogen Idec Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Biogen Idec Multiple Sclerosis (MS) Drugs Product Offerings
7.3.5 Biogen Idec Recent Development
7.4 Cinnagen
7.4.1 Cinnagen Company Information
7.4.2 Cinnagen Introduction and Business Overview
7.4.3 Cinnagen Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Cinnagen Multiple Sclerosis (MS) Drugs Product Offerings
7.4.5 Cinnagen Recent Development
7.5 Daiichi Sankyo
7.5.1 Daiichi Sankyo Company Information
7.5.2 Daiichi Sankyo Introduction and Business Overview
7.5.3 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Product Offerings
7.5.5 Daiichi Sankyo Recent Development
7.6 Eli Lilly
7.6.1 Eli Lilly Company Information
7.6.2 Eli Lilly Introduction and Business Overview
7.6.3 Eli Lilly Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Eli Lilly Multiple Sclerosis (MS) Drugs Product Offerings
7.6.5 Eli Lilly Recent Development
7.7 Fast Forward Llc
7.7.1 Fast Forward Llc Company Information
7.7.2 Fast Forward Llc Introduction and Business Overview
7.7.3 Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Fast Forward Llc Multiple Sclerosis (MS) Drugs Product Offerings
7.7.5 Fast Forward Llc Recent Development
7.8 Antisense Therapeutics
7.8.1 Antisense Therapeutics Company Information
7.8.2 Antisense Therapeutics Introduction and Business Overview
7.8.3 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Product Offerings
7.8.5 Antisense Therapeutics Recent Development
7.9 Apitope
7.9.1 Apitope Company Information
7.9.2 Apitope Introduction and Business Overview
7.9.3 Apitope Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Apitope Multiple Sclerosis (MS) Drugs Product Offerings
7.9.5 Apitope Recent Development
7.10 Five Prime Therapeutics
7.10.1 Five Prime Therapeutics Company Information
7.10.2 Five Prime Therapeutics Introduction and Business Overview
7.10.3 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Product Offerings
7.10.5 Five Prime Therapeutics Recent Development
7.11 Genmab
7.11.1 Genmab Company Information
7.11.2 Genmab Introduction and Business Overview
7.11.3 Genmab Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Genmab Multiple Sclerosis (MS) Drugs Product Offerings
7.11.5 Genmab Recent Development
7.12 Artielle Immunotherapeutics
7.12.1 Artielle Immunotherapeutics Company Information
7.12.2 Artielle Immunotherapeutics Introduction and Business Overview
7.12.3 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2019-2024)
7.12.4 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Offerings
7.12.5 Artielle Immunotherapeutics Recent Development
7.13 Genzyme
7.13.1 Genzyme Company Information
7.13.2 Genzyme Introduction and Business Overview
7.13.3 Genzyme Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2019-2024)
7.13.4 Genzyme Multiple Sclerosis (MS) Drugs Product Offerings
7.13.5 Genzyme Recent Development
7.14 Glaxosmithkline
7.14.1 Glaxosmithkline Company Information
7.14.2 Glaxosmithkline Introduction and Business Overview
7.14.3 Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2019-2024)
7.14.4 Glaxosmithkline Multiple Sclerosis (MS) Drugs Product Offerings
7.14.5 Glaxosmithkline Recent Development
7.15 Gw Pharmaceuticals
7.15.1 Gw Pharmaceuticals Company Information
7.15.2 Gw Pharmaceuticals Introduction and Business Overview
7.15.3 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2019-2024)
7.15.4 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Product Offerings
7.15.5 Gw Pharmaceuticals Recent Development
7.16 Innate Immunotherapeutics
7.16.1 Innate Immunotherapeutics Company Information
7.16.2 Innate Immunotherapeutics Introduction and Business Overview
7.16.3 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2019-2024)
7.16.4 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Offerings
7.16.5 Innate Immunotherapeutics Recent Development
8 Industry Chain Analysis
8.1 Multiple Sclerosis (MS) Drugs Industrial Chain
8.2 Multiple Sclerosis (MS) Drugs Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Multiple Sclerosis (MS) Drugs Sales Model
8.5.2 Sales Channel
8.5.3 Multiple Sclerosis (MS) Drugs Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
Bayer AG
Bayhill Therapeutics
Biogen Idec
Cinnagen
Daiichi Sankyo
Eli Lilly
Fast Forward Llc
Antisense Therapeutics
Apitope
Five Prime Therapeutics
Genmab
Artielle Immunotherapeutics
Genzyme
Glaxosmithkline
Gw Pharmaceuticals
Innate Immunotherapeutics
听
听
*If Applicable.